Michael F. Rafferty, Ph.D. is the Head of Preclinical Research and serves on the Scientific Advisory Board at Grannus. He previously worked as an independent consultant to both large and emerging pharmaceutical companies, advising on discovery and early development programs. He also serves as an Adjunct Professor of Medicinal Chemistry at the University of Kansas. Dr. Rafferty brings decades of experience in drug discovery and preclinical development, having held senior leadership positions at Pfizer and serving as Vice President of Preclinical Development at Deciphera Pharmaceuticals. His academic and industry contributions include serving on the editorial board of Molecular Pharmaceutics, as Co-Editor-in-Chief of Medicinal Research Reviews, and as an ad hoc reviewer for multiple journals in medicinal chemistry and pharmacology. He is also a co-founder of the Medicinal and Bioorganic Chemistry Foundation and previously served on the Scientific Advisory Board at Deciphera. Dr. Rafferty is an inventor on 42 issued U.S. patents and has co-authored 56 peer-reviewed publications. He earned his Ph.D. in Medicinal Chemistry from the University of Kansas and completed a postdoctoral fellowship at the National Institutes of Health.